Meanwhile, the costs and effects of these markers in clinical practice in China were assessed by cost-effectiveness analysis.
Additionally, he has been exploring the normative foundations of health and innovation policy in a number of papers that examine both the opportunities and limits presented by "cost-effectiveness analysis" as a regulatory tool to supplement market or economic-efficiency measures of social welfare.
Drug coverage decision-making is often informed by cost-effectiveness analysis where expected costs and expected outcomes are compared.
A larger number of health interventions assessed by cost-effectiveness analysis would in addition make the subsequent identification of an essential package of health interventions more credible.
It is intended to be used as a practical checklist that helps them to make sure they have considered all the main issues of equity that are not captured by cost-effectiveness analysis.
The present Guidance for Priority Setting in Health Care (GPS-Health) offers a checklist of equity criteria that are relevant to health care priority setting and are not adequately considered by cost-effectiveness analysis.
aNote that the introduction of Meningococcal serogroup B (Men B) has been agreed but has not yet started Decisions to change the immunisation programme are currently made on a case-by-case basis, informed primarily by cost-effectiveness analysis specific to the vaccine change being considered [ 1– 5].
To date, the results from this study have provided a methodological foundation for further work on cost effectiveness analysis by interdisciplinary teams within the Mexican Ministry of Health, at the same time that the findings have informed decision making around provision and financial coverage for several interventions and provided an evidence base for other public health policies.
This analysis follows the standardised methodology on cost effectiveness analysis set forth by the WHO-CHOICE project 12 13 14 and builds on previous analyses of public health interventions to lower systolic blood pressure and cholesterol 15 and of tobacco use.
We add to the literature by presenting a cost effectiveness analysis of IDSR, in which we will assume that any average reductions in health outcomes (e.g., incidence of cases and deaths, outbreak duration) were due to implementation of IDSR.
Given the considerable cost of human albumin in comparison with alternatives 124 and the lack of effect on mortality, we speculate that it is unlikely the use of human albumin would be supported by a contemporary cost effectiveness analysis in the UK National Health Service, although this may not be the case for insurance based healthcare systems.
